Trial · NCT03640351
Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery
NCT03640351, Not applicable, Completed, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery. Trials, record NCT03640351. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03640351
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery
- NCT number
- NCT03640351
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 150 participants, actual
- Lead sponsor
- Yonsei University
- Conditions
- Dry Eye, Cataract Surgery
- Interventions
1. Use of preservative free diquafosol ophthalmic solution after cataract surgery, 2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery, 3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery
- First posted
- 2018-08-21
- Last updated
- 2020-09-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1. Tear break up time (TBUT) at postoperative 3 months among the three groups. | postoperative 3 months | 1\. Tear break up time (TBUT) is examined using slit lamp examination, The unit of this is "sec". Tear break up time (TBUT) at postoperative 3 months will be compared among the three groups. |
| Primary | 2. Tear break up time (TBUT) changes between baseline and postoperative 3 months among the three groups. | postoperative 3 months | 2\. TBUT change from baseline to postoperative 3 months will be compared among the three groups. |
| Primary | 3. Ocular Surface Disease Index (OSDI) at postoperative 3 months among the three groups. | postoperative 3 months | 3\. Ocular Surface Disease Index (OSDI) is examined using questionnaire evaluating dry eye symptom of patient (from 0 to 100). Ocular Surface Disease Index (OSDI) at postoperative 3 months will be compared among the three groups. |
| Primary | 4. Ocular Surface Disease Index (OSDI) changes between baseline and postoperative 3 months among the three groups. | postoperative 3 months | 4\. OSDI change from baseline to postoperative 3 months will be compared among the three groups. |
| Primary | 5. Meibomian gland dysfunction (MGD) stage at postoperative 3 months among the three groups. | postoperative 3 months | 5\. MGD stage is evaluated by examiner (from 0 to 4). OSDI and MGD stage is unitless. MGD stage at postoperative 3 months will be compared among the three groups. |
| Primary | 6. Meibomian gland dysfunction (MGD) stage changes between baseline and postoperative 3 months among the three groups. | postoperative 3 months | 6 MGD stage change from baseline to postoperative 3 months will be compared among the three groups. |
| Secondary | 1. The value of total higher order aberration at postoperative 3 months among the three groups. | postoperative 3 months | 1\. The value of total higher order aberration is examined using iTrace aberrometer (Tracey Technologies Corp. Houston, TX). The unit of those is "μm". The value of total higher order aberration at postoperative 3 months will be compared among the three groups. |
| Secondary | 2. The change of the value of total higher order aberration between baseline and postoperative 3 months among the three groups. | postoperative 3 months | 2\. The change of the value of total higher order aberration from baseline to postoperative 3 months will be compared among the three groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03640351
GET https://conductscience.org/api/trials/v1/NCT03640351/registered